azacitidine and Iron Overload

azacitidine has been researched along with Iron Overload in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chao, X; Chengming, F; Chunkang, C; Juan, G; Shucheng, G; Xi, Z; Xiao, L; Youshan, Z	1
Hofmann, WK; Nolte, F	1
Alimena, G; Breccia, M; Colafigli, G; Federico, V; Finsinger, P; Latagliata, R; Loglisci, G; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A	1

Reviews

1 review(s) available for azacitidine and Iron Overload

Article	Year
[Current treatment options for myelodysplastic syndromes]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:38 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide	2010

Article

Year

[Current treatment options for myelodysplastic syndromes].

Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:38

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide

2010

Other Studies

2 other study(ies) available for azacitidine and Iron Overload

Article	Year
Decitabine treatment could ameliorate primary iron-overload in myelodysplastic syndrome patients. Cancer investigation, 2015, Volume: 33, Issue:4 Topics: Aged; Aged, 80 and over; Azacitidine; Bone Morphogenetic Protein 2; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Ferritins; GPI-Linked Proteins; Hemochromatosis Protein; Hemoglobins; Humans; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes	2015
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. Annals of hematology, 2012, Volume: 91, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles	2012

Article

Year

Decitabine treatment could ameliorate primary iron-overload in myelodysplastic syndrome patients.

Cancer investigation, 2015, Volume: 33, Issue:4

Topics: Aged; Aged, 80 and over; Azacitidine; Bone Morphogenetic Protein 2; Decitabine; DNA Methylation; DNA Modification Methylases; Female; Ferritins; GPI-Linked Proteins; Hemochromatosis Protein; Hemoglobins; Humans; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes

2015

Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.

Annals of hematology, 2012, Volume: 91, Issue:9

Topics: Adult; Aged; Aged, 80 and over; Antimetabolites; Azacitidine; Benzoates; Chelating Agents; Deferasirox; Drug Eruptions; Drug Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematinics; Humans; Iron Overload; Kidney Diseases; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Thalidomide; Treatment Outcome; Triazoles

2012